The implication of mutations in the TGFBR2 gene, known to be involved in cancers, in Marfan syndrome (MFS) and later in Loeys-Dietz syndrome (LDS) and Familial Thoracic Aortic Aneurysms and Dissections (TAAD2) gives a new example of the complexity of one gene involved in multiple diseases. To date, known TGFBR2 mutations are not disease-specific and many mutations have to be accumulated before genotype-phenotype relationships emerge. To facilitate mutational analysis of the TGFBR2 gene, a locus-specific database has been set up with the Universal Mutation Database (UMD) software. The version of the computerized database contains 85 entries. A total of 12 mutations are reported to be involved in MFS, six in incomplete MFS, 30 in LDS type I, 10 in LDS type II, seven in TAAD2, and 20 in various cancers. The database is accessible online at http:// www.umd.be (last accessed: 3 July 2007). Hum Mutat 29(1), 33-38, 2008. r r 2007 Wiley-Liss, Inc.
INTRODUCTION
Many diseases are caused by an inherited variation in just one gene. Among more than 7,000 human rare diseases inherited in a Mendelian fashion (one gene-one disease), nearly 4,000 genes associated with a given phenotype have now been mapped. These molecular genetic analyses identify a more complex scenario in which the same gene can be involved in disorders thought to be clinically distinct. The TGFBR2 gene (MIM] 190182) belongs to this more complex category. Transforming growth factor beta receptor type II (TbR-II) is a transmembrane protein serine/ threonine kinase well known as having a tumor suppressor role and inhibiting cell proliferation. Receptor activation occurs upon binding of TGFb to TbR-II, which then recruits and phosphorylates TbR-I, which propagates the signal to downstream targets, Smads (Fig. 1) . Smad complexes then translocate to the nucleus, where together with a coactivator or a corepressor they regulate transcription of target genes [Attisano et al., 1996; Souchelnytskyi et al., 1996; Ullrich and Schlessinger, 1990; Wieser et al., 1995; Wrana et al., 1994a Wrana et al., , 1994b . Perturbations of the TGFb/Smad signaling system are the cause of various forms of human cancers as well as developmental disorders [Massague, 1998] . With somatic mutations and loss of expression of genes for various components of the TGFb/SMAD signaling pathway, growth inhibition is lost, resulting in unregulated cell growth with tumor formation. A large number of pancreatic and colorectal cancers have mutations in some component of the pathway. Mutations in the gene encoding TbR-II, TGFBR2, usually reported in colon and gastric cancer lead to truncated, inactive TGFBR2 product by mutations in a polyadenosine tract (BatII region) . In most of these cases, both TGFBR2 alleles present with a mutation in the BatII sequence. In some cases, however, a different mutation inactivates the second allele such as loss of heterozygosity, addition of a GT dinucleotide to a (GT) 3 sequence in the kinase domain coding region, or missense mutations predicted to inactivate this kinase domain. TGFBR2 then shares the two-hit inactivation mechanism of other tumor suppressor genes.
In 2004, we demonstrated the implication of six TGFBR2 mutations in Marfan syndrome (MFS) [Mizuguchi et al., 2004] . MFS, the founding member of heritable disorders of connective tissue, is a dominantly inherited condition characterized by tall stature and skeletal deformities, dislocation of the lens, and propensity to aortic dissection. The syndrome is characterized by considerable variation in the clinical presentation between families and also within the same family. The leading cause of premature death is progressive dilation of the aortic root and ascending aorta, causing aortic incompetence and dissection. The average life expectancy has risen significantly since 1972, which is partly due to the benefit arising from aortic follow-up with echocardiography, aortic surgery, and medical therapy with beta blockers. The first mutations involved in classical MFS phenotypes have been found in the FBN1 gene encoding fibrillin-1, the major component of the extracellular matrix [Dietz et al., 1991] . FBN1 mutations have now been identified in a spectrum of phenotypicallyrelated connective tissue disorders, termed type 1 fibrillinopathies, including severe neonatal Marfan syndrome [Kainulainen et al., 1994] , autosomal dominantly inherited ectopia lentis [Kainulainen et al., 1994] , isolated skeletal features (or Marfanoid skeletal syndrome) [Ades et al., 2002; Hayward et al., 1994; Milewicz et al., 1995] , ''MASS phenotype'' (MASS is an acronym that designates the involvement of the mitral valve, aorta, skeleton, and skin) [Dietz et al., 1993] , familial or isolated forms of aortic aneurysms [Milewicz et al., 1996] , and autosomal dominant Weill-Marchesani syndrome [Faivre et al., 2003] . Heterozygous mutations in TGFBR2, a putative tumor-suppressor gene involved in several malignancies, are also associated with MFS [Mizuguchi et al., 2004] . The implication of TGFBR2 mutations, not only in MFS but also in other autosomal dominant Mendelian disorders such as Loeys-Dietz syndrome (LDAA) [Loeys et al., 2005] and Familial Thoracic Aortic Aneurysms and Dissections (TAAD2) [Pannu et al., 2005] , revealed all the complexity of the TGF-b signal transduction network. Mutations in the TGFBR2 gene in MFS2, LDS, and TAAD2 define a new group of Marfan syndrome-related connective tissue disorders: TGFb signalopathies.
To date, known TGFBR2 mutations are not disease-specific and many mutations have to be accumulated before genotype-phenotype relationships emerge. To facilitate mutational analysis of the TGFBR2 gene, and as for FBN1 [Collod et al., 1996; Collod-Beroud et al., 1997 , 1998 , we have created a human TGFBR2 mutation database, Universal Mutation Database (UMD)-TGFBR2. The information regarding these mutations is standardized to facilitate their mutational analysis and, when a greater number of mutations has been collected, identify structure-function and phenotype-genotype relationships. This database gives access to a software package that provides specific routines and optimized multicriteria research and sorting tools [Beroud et al., 2000 [Beroud et al., , 2005 .
THE TGFBR2 GENE AND TBR-II
TGFBR2 gene maps to 3p22 [Mathew et al., 1994] . The TbR-II protein is encoded by 567 codons in seven exons ( Fig. 2A ) [Takenoshita et al., 1996] . The translated product of the TGFBR2 gene is composed of several subdomains (Fig. 2B ). Starting from the Nterminus, there is a signal peptide (1-22) [Lin et al., 1992] , a relatively short cysteine-rich extracellular domain (51-142), serine/threonine protein kinase catalytic domains (codons 246-544), and the Cterminus. The extracellular region is N-glycosylated [Wells et al., 1997] and contains 12 cysteines probably involved in the general folding of this region. Three of these cysteines form a characteristic cluster near the transmembrane sequence [Childs et al., 1993; Massague, 1992] . The transmembrane region and the cytoplasmic juxtamembrane region have no singular structural features. The cytoplasmic region contains kinase domains conforming to the canonical sequence of a serine/threonine protein kinase domain (Hanks et al., 1988) . TbR-II is regulated intricately by autophosphorylation on at least three serine residues (Ser213 in the juxtamembrane region and Ser409 et Ser416 in the T-loop region of the kinase domain [Luo and Lodish, 1997] ). The TbR-II exists in an alternative form arising from the presence of a 25-amino acid insert following the signal sequence [Hirai and Fijita, 1996; Suzuki et al., 1994] . , allowing this protein to associate with coactivator (CO-SMAD) and move into the nucleus. In the nucleus, the SMAD complex associates with a DNA-binding partner and this complex binds to speci¢c enhancers in target genes, activating transcription. Smurfs (Smad^ubiquitin regulatory factor) bind to the activated TGF-b receptor complex via I-Smads. Smurf then ubiquitinates the receptor, causing its rapid proteasomal degradation.The CO-SMAD/R-SMAD can interact with a great number of transcriptional coactivators/corepressors to positively or negatively regulate e¡ector genes, so that the interpretation of a signal depends on the cell-type and cross-talk with other signaling pathways. The database lists known point mutations, deletions or insertions, and splice mutations in the TGFBR2 gene. Its purpose is to collect in a standardized accessible and summary form the molecular and the clinical data on the causative mutations of Marfan syndrome, and TGFb signalopathies and cancers. (A TGFBR1 mutation database is currently under construction.)
The present version of the database contains 85 entries corresponding to mutations either published or only reported in meeting proceedings ( Supplementary Table S1A and B, available online at http://www.interscience.wiley.com/jpages/1059-7794/ suppmat). As in previous editions of the UMD [Beroud et al., 2000 [Beroud et al., , 2005 , mutation names are given according to nomenclature guidelines (www.hgvs.org) and numbered with respect to the TGFBR2 gene cDNA sequence (11 5 A of ATG) obtained from GenBank database (GenBank database accession number BC040499; Homo sapiens transforming growth factor, beta receptor II (70/80 kDa), mRNA (cDNA clone IMAGE:5287742). For each mutation, information is provided at several levels: at the gene level (exon and codon number, wild-type and mutant codon, mutational event, mutation name); at the protein level (wild-type and mutant amino acid, affected domain); and at the clinical level (absence or presence of skeletal, ocular, cardiovascular, central nervous system, and other various manifestations when data are available). In addition, we have annotated the TGFBR2 sequence for highly conserved domains (HCD). These data list for a given position the known arguments such as: transmembrane region, ATP-binding region, proton-acceptor region, posttranslational modification of a residue as N-linked glycosylation or serine phosphorylation (SWISS-PROT accession number P37173) and very conserved amino acids of unknown function (comparison of the HBG054502 gene family).
ANALYSIS OF THE DATABASE
The great majority of the mutations are spread throughout the serine/threonine kinase domains (Fig. 2C) . We have included repeat observations of the same mutation except for the mutations located in the polyadenosine tract (BatII region) (c.383delA, c.382_383delAA and c.382dup) corresponding to the hotspot observed in cancers that are represented once. A total of 36 recurrent mutations have been reported corresponding to 11 mutational events: p.R356P (x2), p.N384S (x2), p.D446N (x2), p.S449F (x2), p.R460C (x3), p.R460H (x6), p.C461Y (x2), p.E526Q (x2), p.R528C (x3), p.R528H (x8), and p.R537C (x4). In these recurrent mutational events, mutations are not disease-specific as the same mutation can be either involved in different genetic diseases, or in cancer and genetic disorder. For example, p.R537C is reported in colon cancer [Lu et al., 1995] , in MFS [Mizuguchi et al., 2004] , and in LDS type I . Today, two recurrent mutations are only involved in LDS type I: p.C461Y and p.R528C . When looking at reported transmissions, 20 somatic mutations are involved in cancers and 17 de novo mutations vs. 16 familial cases are observed. For 28 mutations, detailed data are not available. Mutations are mainly missense with 78 reported cases among which 46 concern highly conserved amino acids. Two nonsense mutations, p.R495X and p.R497X [Singh et al., 2006] , are located in the same region, the cytoplasmic serine/threonine kinase domain DXI. Four splice-site mutations are described. Three concern the canonical splice site sequences (c.95-2A4G, c.1397-2A4G, and c.1397-1G4A) and one is a synonymous amino acid substitution in the last nucleotide of exon 6 resulting in abnormal splicing [Mizuguchi et al., 2004] . For each of the four mutations, insertion or deletion sequences have been experimentally characterized (see Table 1 ). Only one insertion is reported, corresponding to the duplication of one base, c.1600_1601dup .
The p.T315M variation, which was reported initially in familial nonpolyposis colorectal cancer [Lu et al., 1998] , was observed in two patients with MFS and in nine of 497 controls by Ki et al. [2005] . Ki et al. [2005] presumed then that this variation is a rare polymorphism in the Korean population (estimated allele frequency of 0.01). This variation is however considered as probably pathogenic based on chemical properties (Blosum62 [Henikoff and Henikoff, 1992] , and biochemical value [Yu, 2001] ). In the absence of conclusive data, this variation has been classified as a polymorphism. In the same way, sequence variations, c.944C4T [Lu et al., 1998 ], c.1159G4A [Lucke et al., 2001; Matyas et al., 2006] , and c.1159G4C [Matyas et al., 2006] , for which no clear argument for their pathogenicity has been reported are considered as polymorphism until more data are collected (see Supplementary  Table S2 ).
The diagnosis of Shprintzen-Goldberg syndrome reported by Kosaki et al. [2006] in a Korean patient is debatable (c.IVS5-2A4G or c.1397-2A4G mutation). This patient fulfills the preliminary guidelines suggested for the diagnosis of Shprintzen-Goldberg syndrome. However, Robinson et al. [2006] argued that the diagnosis of Loeys-Dietz syndrome would also be appropriate for this individual, especially in light of the presence of bifid uvula and the sigmoid configuration of the brachycephalic, left common carotid, and left subclavian arteries. This patient is then reported as having LDS type I.
Further studies will be now necessary to characterize a large number of germline mutations in this gene and determine if the spectrum of clinical features associated with TGFBR2 gene mutations is as large as that of FBN1 gene mutations.
DATABASE UPDATE
The current database and subsequent updated versions are available at www.umd.be.
Notification of omissions and errors in the current version as well as specific phenotypic data would be gratefully received by the corresponding author (g.collod-beroud@montp.inserm.fr). The software package is available on a collaborative basis. The software will be expanded as the database grows and according to the requirements of its users. New functions could be implemented. Users of the database must cite this article. *Consensus values for each potential donor or accepter splice site are calculated for wild type (WT) and mutant sequence according to Shapiro and Senapathy [1987] and Senapathy et al. [1990] (100 5 strong splice site; 0 5 not a splice site).
Observed consequences describes the abnormalities found at the mRNA level.
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